HerbClinical dose · 300–450mg/day (standardised to at least 50% bacosides)Onset · 8–12 weeks of consistent use (most positive trials ran 12 weeks)

Bacopa Monnieri

Name: Bacopa Monnieri — Human Clinical Effect Matrix
Creator: The Nootropic Lab
License: https://creativecommons.org/licenses/by/4.0/

A meta-analysis of 9 RCTs (Kongkeaw et al., 2014, n=518) found Bacopa shortened Trail Making B and choice reaction times versus placebo, and two 12-week RCTs in healthy older adults (Calabrese 2008; Morgan & Stevens 2010) improved delayed word recall at 300mg/day. The newest 12-week RCT (Lopresti 2025, n=101, 300mg/day) found no effect on verbal learning, attention or working memory, though it did reduce self-reported stress. A 2026 network meta-analysis of 29 RCTs found ≥600mg/day beat 300–450mg/day for working memory. Best evidence is for delayed recall rather than acute effects.

By The Nootropic Lab editorial teamUpdated Oct 15, 20268 min read✓ Fact-checked

Evidence reviewed: Sep 28, 2026

Mechanism of action

Bacopa enhances synaptic communication by increasing dendritic branching and synaptic density. Its active compounds (bacosides A and B) facilitate repair of damaged neurons and upregulate antioxidant activity, reducing oxidative stress in hippocampal tissue. It also modulates serotonin and acetylcholine systems.

Clinical evidence summary

Human effect matrix

Based on human clinical trials only. Animal and in-vitro data excluded.

Effect	Evidence	Magnitude	Studies	Notes
Memory Consolidation	moderate	Moderate	5	Pase 2012 systematic review: Bacopa improved 9 of 17 memory free-recall tests across six 12-week trials; two 12-week RCTs on delayed recall; a 2026 network meta-analysis (working memory, ≥600mg/day). The 2025 Lopresti RCT at 300mg/day did not replicate the memory benefit, and Kongkeaw 2014 pooled speed-of-attention outcomes, not memory.
Anxiety Reduction	moderate	Moderate	2	Calabrese 2008: anxiety fell with Bacopa and rose with placebo over 12 weeks; Lopresti 2025: lower self-reported stress reactivity.
Attention	mixed	Small	2	Positive pooled speed-of-attention result (Kongkeaw 2014) but no effect on attention in the largest recent RCT (Lopresti 2025, p=0.713).
Processing Speed	mixed	Small	2	An acute 320mg dose improved sustained task performance (2012), but the 2026 network meta-analysis found no processing-speed difference.

Evidence key: Strong = multiple consistent RCTs · Moderate = smaller/fewer RCTs · Preliminary = early trials or small n · Mixed = conflicting results

Documented benefits

Delayed recall in healthy older adults (12-week RCTs)
Anxiety and stress reduction
Antioxidant activity (laboratory studies)

Side effects & cautions

GI effects (increased stool frequency, abdominal cramps, nausea) reported at 300mg/day in a 12-week RCT in older adults — take with food
More self-reported adverse reactions than placebo (digestive complaints, headaches) in a 2025 12-week RCT
Slowed information processing initially
Not recommended during pregnancy (precautionary: no human safety data)

How to take

Dosage300–450mg/day (standardised to at least 50% bacosides) — the classic trial dose; ≥600mg/day is an emerging, less-established option

TimingWith your largest meal of the day — morning or evening both work

With foodBacosides are fat-soluble, so a meal with some fat is the standard advice. Taking it with food also helps with the GI side effects reported in trials. Do not take on an empty stomach.

FormsCapsule is most practical. Powder has a bitter, unpleasant taste. Look for an extract standardised to at least 50% bacosides on the label (the positive trial we cite used 300mg of a 50% extract, about 150mg of bacosides) — unstandardised herbal products may contain very little active compound.

Stacking recommendations

Ingredients that pair well with Bacopa Monnieri and why.

Lion's Mane

Both are studied for memory and cognitive function; we cite no trial of the pairing.

Citicoline

Both are studied for memory, and both are in Mind Lab Pro; we cite no trial of the pairing.

L-Theanine

Both are studied for stress and anxiety; we cite no trial of the pairing.

Frequently asked questions

Why do some people feel "foggy" when starting Bacopa?

Slowed information processing at the start is a listed side effect of Bacopa. If it persists past 6 weeks, reduce your dose.

Do I really need to take it with fat?

It is the sensible default. Bacosides are fat-soluble compounds, and GI side effects (cramps, nausea, more frequent stools) were reported in trials, so taking Bacopa with a normal meal that contains some fat is the usual advice.

What percentage of bacosides should I look for?

Aim for at least 50%: the positive trial we cite (Calabrese et al., 2008) used 300mg a day of an extract standardised to a minimum of 50% bacosides, about 150mg of bacosides. Two standardised commercial extracts are Bacognize and Synapsa. Generic "Bacopa" with no standardisation stated is unreliable — the active compound content may be negligible.

How long does it take to work?

The positive memory trials measured outcomes after 12 weeks. This is not a supplement you evaluate in the first month. Set a calendar reminder to assess at around 12 weeks — and note that the newest 12-week trial at 300mg/day found no cognitive benefit, so results vary.

Can Bacopa be taken long-term?

Most trials ran 12 weeks or less, so controlled data beyond that is thin. Traditional Ayurvedic use is continuous without cycling, and no trial has shown cycling is necessary — but long-term safety has not been studied directly.

Top stacks containing Bacopa Monnieri

Mind Lab Pro

7.5/10

Performance Lab

Editor's Choice

NooCube

7/10

Wolfson Brands

Hunter Focus

6.3/10

Roar Ambition

Alpha Brain

5.2/10

Onnit

Bacopa Monnieri in Australia

Bacopa monnieri is a permitted ingredient in the TGA's Permissible Ingredients Determination, listed at Schedule 1 item 754 with purpose codes 'A, H' -- meaning it may be used both as an active ingredient and as a homoeopathic preparation ingredient. Unlike citicoline and theanine, the entry carries no additional ingredient-specific dose cap or label warning statement in the table's requirements column. No AU product reviewed on this site is a current AUST L-listed Bacopa monnieri product. Correction (2026-10-09): earlier versions of this note said the discontinued Blackmores Brain Active listed Bacopa Monnieri; its only active ingredient was Longvida turmeric extract (blackmores.com.au product page, archived 2015-01-13).

What the Determination's 'A, H' purpose code means for Bacopa monnieri

The Determination defines 'active ingredient, or A' and 'homoeopathic preparation ingredient or H' as the two purpose categories a Schedule 1 entry can carry; Bacopa monnieri, at item 754, is assigned both, meaning a sponsor can use it as an active ingredient in a listed medicine or as a constituent of a homoeopathic preparation. No ingredient-specific dose limit or warning statement appears in the requirements column for this entry, unlike citicoline's 500 mg cap or theanine's 450 mg cap in the same Determination -- though the general obligations the instrument sets for all Schedule 1 ingredients still apply.

Products in Australia

TGA (AUST L)

Does the TGA cap the dose of Bacopa monnieri in a listed medicine?

Not with an ingredient-specific figure. Schedule 1 item 754 lists Bacopa monnieri with purpose codes 'A, H' (active ingredient and homoeopathic ingredient) and no additional requirements, unlike citicoline's 500 mg cap or theanine's 450 mg cap in the same Determination.

Is there an AUST L-listed Bacopa monnieri product reviewed on this site?

No current one. The reviewed products with Bacopa Monnieri as a hero ingredient (noocube-review, onnit-alpha-brain-review) show no AUST L number in this site’s Australian catalogue, and no matching entry was returned for them by product or sponsor name in the Australian Register of Therapeutic Goods (ARTG) search or the cancellations-by-sponsor database (searched 2026-10-06). Earlier versions of this answer named Blackmores Brain Active; it did not contain Bacopa (its only active ingredient was Longvida turmeric extract).

State & territory guides

Sources: Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940) -- Schedule 1, item 754 (Bacopa monnieri) · Blackmores Brain Active product page, blackmores.com.au (Internet Archive snapshot 2015-01-13) · Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940) -- definitions · Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940) -- definitions

Regulatory note

Therapeutic goods available in Australia are regulated by the Therapeutic Goods Administration (TGA). AUST L–listed products carry pre-approved permitted indications; AUST R–registered products are higher-evidence. Imported products without TGA listing are not assessed by Australian regulators. This page is editorial, not promotional, and does not constitute medical advice. Always read the label and follow directions for use. Consult a qualified healthcare professional before starting any supplement.

Sources (7)expand

← Back to Ingredients Guide